Evidence map›Paper›PMID 29269885›Full record

ArticleScientific reports2017

Mesenchymal Stem Cell-Conditioned Medium Reduces Disease Severity and Immune Responses in Inflammatory Arthritis.

Alasdair G Kay, Grace Long, George Tyler, Andrei Stefan, Stephen J Broadfoot, Anna M Piccinini, Jim Middleton, Oksana Kehoe

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 2 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 2 syntheses or guidelines pooled it, 156 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Alasdair G KayBiology Department, University of York, Wentworth Way, York, UK.
Grace LongSchool of Medicine, Keele University, Staffordshire, UK.
George TylerSchool of Medicine, Keele University, Staffordshire, UK.
Andrei StefanISTM at RJAH Orthopaedic Hospital, Keele University, Oswestry, UK.
Stephen J BroadfootLSSU, Liverpool John Moore's University, Liverpool, UK.
Anna M PiccininiSchool of Pharmacy, University of Nottingham, Nottingham, UK.
Jim MiddletonFaculty of Health Sciences, School of Oral and Dental Science, University of Bristol, Bristol, UK.
Oksana KehoeISTM at RJAH Orthopaedic Hospital, Keele University, Oswestry, UK. o.kehoe@keele.ac.uk.
Keele University · GBRobert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust · GBLiverpool John Moores University · GBUniversity Of Bristol Dental Hospital · GBUniversity of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the therapeutic potential of mesenchymal stem cell-conditioned medium (CM-MSC) as an alternative to cell therapy in an antigen-induced model of arthritis (AIA). Disease severity and cartilage loss were evaluated by histopathological analysis of arthritic knee joints and immunostaining of aggrecan neoepitopes. Cell proliferation was assessed for activated and naïve CD4+ T cells from healthy mice following culture with CM-MSC or co-culture with MSCs. T cell polarization was analysed in CD4+ T cells isolated from spleens and lymph nodes of arthritic mice treated with CM-MSC or MSCs. CM-MSC treatment significantly reduced knee-joint swelling, histopathological signs of AIA, cartilage loss and suppressed TNFα induction. Proliferation of CD4+ cells from spleens of healthy mice was not affected by CM-MSC but reduced when cells were co-cultured with MSCs. In the presence of CM-MSC or MSCs, increases in IL-10 concentration were observed in culture medium. Finally, CD4+ T cells from arthritic mice treated with CM-MSC showed increases in FOXP3 and IL-4 expression and positively affected the Treg:Th17 balance in the tissue. CM-MSC treatment reduces cartilage damage and suppresses immune responses by reducing aggrecan cleavage, enhancing Treg function and adjusting the Treg:Th17 ratio. CM-MSC may provide an effective cell-free therapy for inflammatory arthritis.

Indexed as

Mesenchymal Stem CellsAnimalsArthritis, ExperimentalCartilage, ArticularCD4-Positive T-LymphocytesCell ProliferationCulture Media, ConditionedKnee JointMaleMiceSeverity of Illness IndexT-Lymphocytes, RegulatoryCulture Media, Conditioned

Identifiers

PMID29269885
PMCPMC5740178
OpenAlexW2772090434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.